Uni-Bio Science Group Limited FY2025 Annual Report: Record Profits, Strong Cash, Dividend Hike, and Strategic Innovation Push

Key Financial Highlights for Investors

• Revenue Growth: 6.0% YoY increase, reaching a record HK\$586.2 million.
• Net Profit: Soared by 12.7% YoY to HK\$93.3 million, with net profit margin at an all-time high of 15.9%.
• Earnings Per Share: HK\$1.56 cents, up 15.5% YoY, with a CAGR of 18.55% from 2023 to 2025.
• Operating Cash Flow: Increased by 32.7% YoY; free cash flow up 27.3% YoY.
• Cash Ratio: Substantial improvement from 0.53x to 1.63x, underscoring a robust liquidity position.
• Final Dividend: Board recommends a final dividend of HK\$0.313 cents per share, up from HK\$0.277 cents in 2024 (13% increase).
• Balance Sheet: Gearing ratio dropped to 19.13% (from 26.13%), and debt-to-equity ratio improved to 40.3% (from 58.9%).
• Operational Efficiency: Cash conversion cycle improved from 124 to 107 days.

Strategic and Operational Developments

• Eight Commercialized Products: The company has a diversified and mature product portfolio, reinforcing its revenue base.
• New Manufacturing Facility: Construction is progressing steadily, with operations targeted to commence in 2027. This is expected to moderate capital expenditure requirements going forward.
• Transition to Innovation-Driven Growth: With policy support in China and the easing of volume-based procurement pressure, Uni-Bio is strategically pivoting from “Stable Growth” to “Innovation-Driven Development”. This transition is expected to support long-term sustainable growth and margin expansion.
• International Out-Licensing: The company is well-positioned to capture emerging out-licensing opportunities in overseas markets, supported by a strong R&D pipeline.

Awards and Industry Recognition

• Received the “2025 Most Promising ESG Potential Award for Hong Kong Stocks”.
• Named “Company of the Year” by South China Morning Post, reflecting leadership in financial strength, innovation, and ESG excellence.

Dividend Policy and Shareholder Returns

• Dividend Increase: The proposed final dividend marks a 13% YoY increase, reflecting management’s confidence in sustained cash generation and profitability.
• Distribution from Share Premium: The dividend will be paid out of the share premium account, subject to shareholder approval and compliance with Cayman Islands law.
• Record Date: Shareholders on record as of 3 June 2026 will be entitled to the dividend, payable on or about 12 June 2026, pending AGM approval on 26 May 2026.

Corporate Governance and Risk Management

• The company maintains full compliance with Hong Kong Listing Rules and robust internal controls. Annual review confirms systems are adequate and effective, with no significant weaknesses or failings identified.
• Audit, Remuneration, and Nomination Committees are fully independent, with all directors confirming compliance with the Model Code for Securities Transactions.
• Directors’ remuneration policy is competitive but not excessive, aiming to attract and retain key talent.

Shareholding and Insider Ownership

• Major Shareholders: Kingsley Leung (Chairman) and associated entities hold approximately 30.37% of the company.
• No directors or major shareholders have conflicts of interest or interests in significant contracts, customers, or suppliers.

Connected Transactions and Related Party Loans

• Extension of Connected Loans: In July and December 2025, the Group extended RMB12.64 million in connected-party loans to a unified maturity date of 31 December 2025, at 3.1% p.a. The loans are secured by patents and support R&D activities. These transactions, though connected, were approved by the board (with interested parties abstaining) and deemed on fair, reasonable, and market terms. Details were disclosed under Chapter 14A of the Listing Rules.

Environmental, Social, and Governance (ESG) Commitments

• ESG remains a top priority, with continuous improvement in green initiatives, energy efficiency, and compliance with environmental laws in both Hong Kong and the PRC.
• The company has adopted green practices and has been recognized for ESG leadership.

Share Options and Incentive Schemes

• Active share option schemes are in place for directors, employees, consultants, and key partners, with clear disclosure of outstanding and exercisable options.
• As of the report date, 193,240,000 shares are available for issue under the 2006 Scheme, representing approximately 3.15% of issued shares. The 2016 Scheme remains active for incentivizing key stakeholders.

Significant Financial Events and Investments

• No major acquisitions, disposals, or investments were made during the year.
• No donations were made in 2025, compared to HK\$1.84 million in 2024.

Risks and Outlook

• The company faces typical industry risks such as regulatory changes and market competition, but maintains a strong risk management and internal control framework.
• Management expresses confidence in delivering sustainable growth, supported by strong financials and innovation-driven strategy.

Five-Year Financial Performance Summary

Potential Share Price Sensitivity & Shareholder Considerations

• Dividend Growth: The 13% increase in the final dividend may positively impact share price sentiment, especially given the improved cash position and profitability.
• Innovation-Driven Strategy: The company’s strategic shift towards innovation and international out-licensing could catalyze future growth, potentially driving further valuation upside.
• Strong Cash Generation and Balance Sheet: Improved cash ratios, lower gearing, and higher free cash flow enhance the company’s financial flexibility, supporting both R&D investment and shareholder returns.
• Recognition and ESG Awards: Prestigious industry awards and ESG accolades may further boost investor confidence and support share valuations.
• Connected Loans: Shareholders should monitor ongoing related-party transactions for any impact on risk profile or future disclosures.
• Manufacturing Expansion: The anticipated new facility in 2027 is a critical long-term growth driver and could become a catalyst for re-rating as completion nears.

Conclusion

Uni-Bio Science Group Limited has delivered record earnings and a substantial dividend increase, while solidifying its strategic focus on innovation and global expansion. With a strong balance sheet, enhanced cash flow, and industry recognition, the company appears well-positioned for continued growth. Shareholders should closely watch the company’s execution on new manufacturing and R&D initiatives, as well as any further international licensing deals, as these could have a material impact on future share price performance.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should review the full annual report and consult their financial advisors before making investment decisions. The author does not hold any position in Uni-Bio Science Group Limited at the time of writing.

View UNI-BIO GROUP Historical chart here